Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974580 | 0.90 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28006945 | 0.88 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL19303444 | 0.86 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL27979205 | 0.86 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL19223345 | 0.86 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL31192375 | 0.85 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29084627 | 0.85 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28036977 | 0.85 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL11266890 | 0.85 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30729687 | 0.84 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024075022-A2 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2024-04-11 | — | — | WO | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023166314-A2 | RNA MOLECULE | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-09-07 | — | — | WO | claimed |
| WO-2023052531-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2023-04-06 | — | — | WO | claimed |
| WO-2023051926-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2023-04-06 | — | — | WO | claimed |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | GENZYME CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250281596-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. | 2025-09-11 | — | — | US | disclosed |
| WO-2025036992-A1 | RNA CONJUGATES | CureVac SE (DE) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4395901-A1 | COMPOSITIONS AND METHODS FOR MODULATING KRAS EXPRESSION | Molecular Axiom, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20070229648-A1 | EXPOSURE DEVICE AND IMAGE FORMING APPARATUS USING THE SAME | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1576138-A2 | 2-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | Idenix (Cayman) Limited (KY) | 2005-09-21 | — | — | EP | disclosed |
| EP-1523489-A2 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-04-20 | — | — | EP | disclosed |
| EP-1263986-A4 | PLATFORM FOR THE DISCOVERY OF THE BACTERIAL GENES INVOLVED IN RNA MODIFICATION | TAO BIOSCIENCES LLC (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004002999-A2 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| EP-1263986-A1 | PLATFORM FOR THE DISCOVERY OF THE BACTERIAL GENES INVOLVED IN RNA MODIFICATION | Montclair Group (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062981-A1 | PLATFORM FOR THE DISCOVERY OF THE BACTERIAL GENES INVOLVED IN RNA MODIFICATION | MONTCLAIR GROUP (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281596-A1 | IONIZABLE CATIONIC COMPOUND | SLC11A2, ABCB4, ARG2 | SLC28A1 467/4885SLC28A2 415/4885SLC29A1 190/4885 |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | CD2BP2, CD2, CD4 | SLC28A1 2826/4885SLC28A2 2444/4885SLC29A1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.